# Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

> **NCT04695431** · — · COMPLETED · sponsor: **Blueprint Medicines Corporation** · enrollment: 317 (actual)

## Conditions studied

- Advanced Systemic Mastocytosis
- Aggressive Systemic Mastocytosis
- Systemic Mastocytosis With an Associated Hematological Neoplasm
- Mast Cell Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04695431
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-04
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2022-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695431, "Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04695431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*